Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CODX 
Co-Diagnostics Inc (CODX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CODX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -80.88% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.47M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 274184 | Beta 1.3 | 52 Weeks Range 0.28 - 2.23 | Updated Date 04/2/2025 |
52 Weeks Range 0.28 - 2.23 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-12 | When Before Market | Estimate -0.34 | Actual -0.3778 |
Profitability
Profit Margin - | Operating Margin (TTM) -7973.9% |
Management Effectiveness
Return on Assets (TTM) -31.45% | Return on Equity (TTM) -53.65% |
Valuation
Trailing PE - | Forward PE 16 | Enterprise Value -25075836 | Price to Sales(TTM) 2.67 |
Enterprise Value -25075836 | Price to Sales(TTM) 2.67 | ||
Enterprise Value to Revenue 0.06 | Enterprise Value to EBITDA 0.52 | Shares Outstanding 31929800 | Shares Floating 31242702 |
Shares Outstanding 31929800 | Shares Floating 31242702 | ||
Percent Insiders 6.37 | Percent Institutions 17.14 |
Analyst Ratings
Rating 3 | Target Price 1.5 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Co-Diagnostics Inc
Company Overview
History and Background
Co-Diagnostics Inc. was founded in 2013. It focuses on developing and manufacturing molecular diagnostic tests, primarily utilizing its patented CoPrimer technology. Initially focusing on infectious diseases, it gained prominence during the COVID-19 pandemic.
Core Business Areas
- Molecular Diagnostics: Develops and manufactures real-time PCR (polymerase chain reaction) tests for detecting infectious diseases, including COVID-19, influenza, and other pathogens.
- CoPrimer Technology: Patented technology designed to enhance the accuracy and efficiency of PCR-based diagnostic tests.
- Custom Assay Development: Offers custom assay development services for specific diagnostic needs.
Leadership and Structure
Dwight Egan is the CEO and Chairman of the Board. The company has a typical corporate structure with departments for R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Logix Smart COVID-19 Test: A real-time PCR diagnostic test for detecting SARS-CoV-2. Market share is difficult to pinpoint precisely, but its sales saw a significant increase during the pandemic. Competitors include Roche (RHHBY), Abbott (ABT), and Thermo Fisher Scientific (TMO).
- Logix Smart ABC Test: A multiplex PCR test for the detection of influenza A, influenza B, and SARS-CoV-2. Competitors include Roche (RHHBY), Abbott (ABT), and Thermo Fisher Scientific (TMO).
- CoPrimer Technology Licensing: Licenses its CoPrimer technology to other diagnostic companies. Revenue varies depending on licensing agreements. Competitors include companies offering similar PCR enhancing technologies, though Co-Diagnostics asserts the uniqueness of their CoPrimer approach.
Market Dynamics
Industry Overview
The molecular diagnostics market is experiencing growth, driven by advancements in technology and increasing demand for rapid and accurate disease detection. The market is competitive, with numerous companies offering a range of diagnostic solutions.
Positioning
Co-Diagnostics positions itself as a provider of high-quality, affordable, and accessible molecular diagnostic solutions, particularly in underserved markets. Its CoPrimer technology is a key differentiator.
Total Addressable Market (TAM)
The global molecular diagnostics market is projected to reach hundreds of billions of dollars. Co-Diagnostics, while not a major player in the entire market, is positioned to capture a share through its targeted diagnostic tests and CoPrimer technology.
Upturn SWOT Analysis
Strengths
- Proprietary CoPrimer technology
- Fast assay development capabilities
- Focus on affordable diagnostics
- Strong performance during the COVID-19 pandemic
Weaknesses
- Reliance on a small number of products
- Dependence on government regulations and approvals
- Fluctuations in testing demand (e.g., post-COVID)
- Smaller scale compared to major competitors
Opportunities
- Expansion into new geographic markets
- Development of new diagnostic assays for other diseases
- Strategic partnerships and collaborations
- Increased adoption of molecular diagnostics in point-of-care settings
Threats
- Competition from larger, more established companies
- Changes in government regulations and reimbursement policies
- Emergence of new diagnostic technologies
- Decline in demand for COVID-19 testing
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Abbott (ABT)
- Thermo Fisher Scientific (TMO)
Competitive Landscape
Co-Diagnostics competes with larger, more established companies with greater resources. Its advantage lies in its CoPrimer technology and focus on affordable diagnostics, allowing it to compete in specific niches and underserved markets.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Experienced rapid growth during the COVID-19 pandemic due to high demand for testing.
Future Projections: Future growth is dependent on expanding its product portfolio beyond COVID-19 and entering new markets.
Recent Initiatives: Focusing on developing new assays for other infectious diseases and expanding its distribution network.
Summary
Co-Diagnostics experienced significant growth during the COVID-19 pandemic, largely due to demand for its COVID-19 tests. However, post-pandemic, their financial performance is highly volatile. They must successfully diversify their product portfolio and expand into new markets to sustain long-term growth. Competition is intense, and success relies on continued innovation and strategic partnerships.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
PCRX
Pacira BioSciences, Inc.
PCRX
Pacira BioSciences, Inc.
QDEL
Quidel Corporation
QDEL
Quidel Corporation
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Co-Diagnostics Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2017-07-12 | Chairman & CEO Mr. Dwight H. Egan | ||
Sector Healthcare | Industry Medical Devices | Full time employees 155 | Website https://co-dx.com |
Full time employees 155 | Website https://co-dx.com | ||
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.